Paul Capital Partners

Carbon Black, Inc. is a prominent provider of cybersecurity solutions focused on endpoint and server security, operating in the United States and internationally. The company offers a comprehensive range of products designed to predict, prevent, detect, respond to, and remediate cyber threats, thereby averting potential data breaches and damaging incidents. Its key offerings include the CB Predictive Security Cloud, which leverages big data analytics for endpoint data collection and threat detection, as well as products like CB Defense, a next-generation antivirus and endpoint detection solution, and CB ThreatHunter, which provides visibility for security operations. Additionally, Carbon Black offers real-time solutions such as CB LiveOps and a managed service called CB ThreatSight. The company serves a diverse client base, including security-focused enterprises, government agencies, and small to mid-sized organizations. Founded in 2002 and headquartered in Waltham, Massachusetts, Carbon Black was previously known as Bit9, Inc. and became a subsidiary of VMware, Inc. in 2019.

Recyclebank is dedicated to promoting sustainability by incentivizing individuals to adopt eco-friendly behaviors. The organization rewards users for making environmentally conscious decisions in their daily lives, such as recycling and reducing waste. Participants earn points that can be redeemed for discounts and offers from local and national businesses, encouraging greater community involvement in sustainability efforts. By fostering a culture of environmentally responsible choices, Recyclebank aims to inspire individuals to contribute to a more sustainable future.

Tethys BioScience, Inc. engages in the discovery, development, and commercialization of biological markers. Its products are used to diagnosis the metabolic diseases, such as diabetes. The company offers PreDx Diabetes Risk Test, a diagnostic test that analyzes a set of multiple proteins and other blood borne biomarkers implicated in the development of diabetes. Tethys BioScience, Inc. was founded in 2002 and is based in Emeryville, California.

Phase III Development is a Software Engineering company with expertise in a wide variety of development technologies. The mission is to provide customers with innovative custom software solutions of superior quality. They deliver on budget and on time.

UCB SA is a biopharmaceutical company based in Belgium that specializes in developing therapies for central nervous system and immunology diseases. The company offers a range of products, including Cimzia for inflammatory diseases, Vimpat and Briviact for epilepsy, Neupro for Parkinson’s disease, and Nayzilam for seizure clusters. Additionally, UCB provides treatments for allergies, osteoporosis, and conditions such as Crohn's disease and rheumatoid arthritis. The company is actively engaged in research and development, focusing on innovative therapies for conditions such as drug-resistant epilepsy and systemic lupus erythematosus. UCB has established collaborations with various organizations, including academic institutions and other pharmaceutical companies, to enhance its therapeutic offerings. Founded in 1928 and headquartered in Brussels, UCB operates research facilities across several countries and remains committed to addressing severe diseases through its product portfolio and ongoing innovation efforts.

SpePharm is a European specialty pharmaceutical company dedicated to acquiring, registering and marketing high medical value medicines throughout Europe, essentially for the hospital market. The SpePharm management team has a wealth of global experience within the pharmaceutical industry. In particular, the team has a well-established and in-depth knowledge of the European regulatory system, the hospital market, and niche and orphan products, with novel approaches and proven successes.

On-X Life Technologies develops, manufactures, and offers artificial heart valve replacement and repair products. The company’s product portfolio includes Aortic Heart Valve with Standard Sewing Ring, Aortic Heart Valve with Conform-X Sewing Ring, Aortic Heart Valve with Anatomic Sewing Ring, Mitral Heart Valve with Standard Sewing Ring, Mitral Heart Valve with Conform-X Sewing Ring, Ascending Aortic Prosthesis, Chord-XTM ePTFE Suture, CO2 diffusion catheters, and more. On-X Life Technologies was incorporated in 1994 and is based in Austin, Texas.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Roxy is a female sports fashion brand based in Costa Mesa, California, specializing in apparel and accessories. The company offers a diverse range of products, including clothing, swimwear, handbags, backpacks, and shoes, catering to the varied preferences and budgets of its customers. By focusing on women's sports fashion, Roxy aims to provide stylish and functional options for active lifestyles.

eVentures Group operates and invests in internet communications companies.